Posted by Michael Wonder on 27 Apr 2021
Health Canada initiates the review of the rolling submission for the first Canadian based COVID-19 vaccine candidate
23 April 2021 - Medicago is pleased to announce that Health Canada received for review the first portion of Medicago’s plant-derived adjuvanted COVID-19 vaccine candidate rolling submission on 19 April 2021.
The Interim Order (IO) rolling submission allows Medicago to submit non-clinical sections, quality and clinical safety, and efficacy information as they become available for Health Canada’s immediate review to accelerate the overall review process.
Health Canada will not decide on whether to authorise any vaccine being considered under the IO rolling review until it has received the complete evidence to support the risk/benefit decision based on safety, efficacy and quality of the COVID-19 vaccine candidate.
